Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab
may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving
combination chemotherapy together with bevacizumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
with bevacizumab works in treating patients with stage IV colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Miami University of Miami Sylvester Comprehensive Cancer Center